2. Academic Validation
  3. Aminofurazans as potent inhibitors of AKT kinase

Aminofurazans as potent inhibitors of AKT kinase

  • Bioorg Med Chem Lett. 2009 Mar 1;19(5):1508-11. doi: 10.1016/j.bmcl.2009.01.002.
Meagan B Rouse 1,  Mark A Seefeld,  Jack D Leber,  Kenneth C McNulty,  Lihui Sun,  William H Miller,  Shuyun Zhang,  Elisabeth A Minthorn,  Nestor O Concha,  Anthony E Choudhry,  Michael D Schaber,  Dirk A Heerding
Affiliations

Affiliation

  • 1 Oncology Chemistry, GlaxoSmithKline, Collegeville, PA 19426, USA.
PMID: 19179070 DOI: 10.1016/j.bmcl.2009.01.002
Abstract

Akt inhibitors containing an imidazopyridine aminofurazan scaffold have been optimized. We have previously disclosed identification of the Akt Inhibitor GSK690693, which has been evaluated in clinical trials in Cancer patients. Herein we describe recent efforts focusing on investigating a distinct region of this scaffold that have afforded compounds (30 and 32) with comparable activity profiles to that of GSK690693.

Figures